Эпидемиология и вакцинопрофилактика (Jul 2021)

Rate of Detecting Positive Markers of Covid-19 in Persons with Various Vaccination Anamnesis

  • P. V. Tsygankov,
  • A. B. Alnikin,
  • I. V. Kvashe,
  • S. V. Shlyk,
  • G. G. Kharseeva,
  • O. A. Ryabtseva,
  • I. V. Tarabanova

DOI
https://doi.org/10.31631/2073-3046-2021-20-3-4-7
Journal volume & issue
Vol. 20, no. 3
pp. 4 – 7

Abstract

Read online

Relevance. Currently, the incidence of COVID-19 is growing in many countries of the world, including Russia. There are suggestions about a likely protective role against the new coronavirus infection of widely used traditional vaccines against respiratory infections (influenza, tuberculosis, pneumococcal infection). Those vaccinated with these vaccines are less likely to report deaths and severe forms of COVID-19 diseases in vulnerable populations.The aim is to determine the frequency of detection of positive markers of a new coronavirus infection in individuals with different vaccination histories.Materials and methods. We examined 313 employees of an educational institution with various vaccination histories at the age of 20–54 years from May to September 2020. The determination of SARS-CoV-2 RNA and specific IgM and IgG antibodies to the virus nucleocapsid was carried out.Results. Positive markers for SARS-CoV-2 (PCR and / or ELISA) were found in 51 (16.3%) people. All examined patients had no signs of acute respiratory viral infections. Among people with positive markers of coronavirus infection (PCR and / or ELISA), the number of people vaccinated against diphtheria, tetanus, measles and hepatitis B (HBV) was 13.7–17.6% of those examined. Among those with negative PCR results, the number of people vaccinated against these infections was higher (p ≤ 0.05) and amounted to 51.0–56.6%. Similar results were found in the determination of specific IgM and IgG.Conclusion. Positive markers of a new coronavirus infection were found much less frequently in persons who had a history of vaccination with ADS-M-toxoid, measles and hepatitis B vaccines.

Keywords